Stephen D Mikolajczyk

FISH-based determination of HER2 status in circulating tumor cells isolated with the microfluidic CEE™ platform.

F. Bischoff, J. Mayer, Tam Pham, 2011, Cancer genetics.

A novel platform for detection of CK+ and CK- CTCs.

Anil K Sood, Lee M Ellis, Michael T Deavers, 2011, Cancer discovery.

Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer.

Stephen D Mikolajczyk, S. Mikolajczyk, H. Rittenhouse, 2003, The Keio journal of medicine.

Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease.

Leonard S Marks, L. Marks, Stephen D Mikolajczyk, 2003, Clinical chemistry.

Twenty Years of PSA: From Prostate Antigen to Tumor Marker.

Axel Semjonow, A. Semjonow, Stephen D Mikolajczyk, 2007, Reviews in urology.

Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.

S. Shariat, B. Miles, D. Kadmon, 2004, Urology.

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen.

Georg Bartsch, Helmut Klocker, William J Catalona, 2004, The Journal of urology.